Literature DB >> 18438857

A novel tumor necrosis factor alpha-responsive CCAAT/enhancer binding protein site regulates expression of the cartilage-derived retinoic acid-sensitive protein gene in cartilage.

Toshihiro Imamura1, Chisako Imamura, Audrey McAlinden, Sherri R Davies, Yukihide Iwamoto, Linda J Sandell.   

Abstract

OBJECTIVE: Inflammatory processes in rheumatoid arthritis are primarily regulated by the cytokines tumor necrosis factor alpha (TNFalpha) and interleukin-1beta (IL-1beta). Previous studies in our laboratory have shown that IL-1beta represses expression of the cartilage characteristic genes, cartilage-derived retinoic acid-sensitive protein (cd-rap) and type II collagen (COL2A1); this mechanism of repression involves activation of a CCAAT/enhancer binding protein (c/EBP) site within promoter regions. The aim of this study was to investigate novel TNFalpha-mediated mechanisms that regulate the expression of cd-rap.
METHODS: Rat chondrosarcoma cells were transiently transfected with complementary DNA constructs encoding cd-rap, in the presence of TNFalpha. The expression of c/EBPbeta, SOX9, and p300 in rat chondrosarcoma cells and primary human articular chondrocytes after treatment with TNFalpha was examined by reverse transcription-polymerase chain reaction and Western blotting. The effect of TNFalpha on endogenous binding of c/EBPbeta or SOX9 to the cd-rap promoter was examined by chromatin immunoprecipitation assays.
RESULTS: We identified a new c/EBP binding site in the cd-rap promoter (from position -1059 bp to position -1046 bp). Binding of c/EBP to this site was regulated by TNFalpha but not IL-1beta, resulting in down-regulation of cd-rap expression. This effect was reversed by mutational inactivation of the c/EBP motif. In addition, the activation potential of SOX9 and CREB binding protein/p300 on the cd-rap promoter was enhanced after mutation of the new c/EBP binding site, indicating that blockage of this site would increase transcription.
CONCLUSION: TNFalpha regulates the expression and/or DNA-binding potential of key positive-acting and negative-acting transcription factors that control the expression of the cartilage matrix gene, cd-rap.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18438857     DOI: 10.1002/art.23438

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  6 in total

1.  Resistin induces expression of proinflammatory cytokines and chemokines in human articular chondrocytes via transcription and messenger RNA stabilization.

Authors:  Zhiqi Zhang; Xiaoyun Xing; Gretchen Hensley; Li-Wei Chang; Weiming Liao; Yousef Abu-Amer; Linda J Sandell
Journal:  Arthritis Rheum       Date:  2010-07

2.  CCAAT/enhancer-binding protein β and NF-κB mediate high level expression of chemokine genes CCL3 and CCL4 by human chondrocytes in response to IL-1β.

Authors:  Zhiqi Zhang; Jennifer L Bryan; Elizabeth DeLassus; Li-Wei Chang; Weiming Liao; Linda J Sandell
Journal:  J Biol Chem       Date:  2010-08-11       Impact factor: 5.157

Review 3.  Epigenomic and microRNA-mediated regulation in cartilage development, homeostasis, and osteoarthritis.

Authors:  Mary B Goldring; Kenneth B Marcu
Journal:  Trends Mol Med       Date:  2011-12-17       Impact factor: 11.951

Review 4.  Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism.

Authors:  M B Goldring; M Otero; K Tsuchimochi; K Ijiri; Y Li
Journal:  Ann Rheum Dis       Date:  2008-12       Impact factor: 19.103

5.  Resistin stimulates expression of chemokine genes in chondrocytes via combinatorial regulation of C/EBPβ and NF-κB.

Authors:  Ziji Zhang; Zhiqi Zhang; Yan Kang; Changhe Hou; Xin Duan; Puyi Sheng; Linda J Sandell; Weiming Liao
Journal:  Int J Mol Sci       Date:  2014-09-26       Impact factor: 5.923

6.  C/EBPbeta Promotes transition from proliferation to hypertrophic differentiation of chondrocytes through transactivation of p57.

Authors:  Makoto Hirata; Fumitaka Kugimiya; Atsushi Fukai; Shinsuke Ohba; Naohiro Kawamura; Toru Ogasawara; Yosuke Kawasaki; Taku Saito; Fumiko Yano; Toshiyuki Ikeda; Kozo Nakamura; Ung-Il Chung; Hiroshi Kawaguchi
Journal:  PLoS One       Date:  2009-02-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.